Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ulcerative Colitis: full-pipeline trial registry
45 of 123 indexed Ulcerative Colitis trials are currently recruiting.
Corpus placement: #97 of 28,707 conditions by registered trial count.
123 US clinical trials · 45 currently recruiting · #97 of 28,707 conditions by registered trial count
Ulcerative Colitis: 123 US clinical trials tracked, 45 recruiting.
Ulcerative Colitis is the subject of 123 registered US clinical trials on ClinicalTrials.gov, 45 of them currently open to new participants. 32 are in Phase 3-4 (later-stage) and 47 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 9 of these trials.
Enrollment posture brief
Registry condition ulcerative-colitis
OPEN 45 | RECR 37% | LATE 32 | EARLY 47 | RANK #97 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Type 2 Diabetes (37% recruiting · 328 trials)
Ulcerative Colitis lists 45 open slots (37% of 123 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ulcerative Colitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ulcerative Colitis recruits in line with its size-band peers.
45 of 123 indexed trials (36.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Ulcerative Colitis trials is spread across many organizations.
Eli Lilly and Company accounts for 9 of 123 trials (7.3%). 72 distinct sponsors appear on at least one study for this condition label.
-
Typical Ulcerative Colitis enrolment sits around 118 participants.
Median target enrolment is 118 among the 123 trials that report a genuine target (sentinel values excluded). 56 of those (45.5%) plan for fewer than 100 participants.
-
Ulcerative Colitis research is mostly interventional.
103 interventional and 20 observational studies make up this index (83.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
123 total, page 2 of 3
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT04033445
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
Eli Lilly and Company
NCT03519945
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Merck Sharp & Dohme
NCT06052059
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
Pfizer
NCT03950232
An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis
Janssen Biotech
NCT02808780
Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease
The Cleveland Clinic
NCT04827368
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
Gilead Sciences
NCT06290934
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
Eli Lilly and Company
NCT05767021
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
AbbVie
NCT06257875
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
AnaptysBio
NCT06127043
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
Beth Israel Deaconess Medical Center
NCT04835506
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
University of Maryland, Baltimore
NCT05316584
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
AbbVie
NCT05782907
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
Pfizer
NCT04624230
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
AltruBio
NCT06109441
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
Boehringer Ingelheim
NCT06636656
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
Northwestern University
NCT04767984
Aquamin® as an Adjuvant Intervention for Ulcerative Colitis
Muhammad N Aslam, MD
NCT03869905
Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis
Rush University Medical Center
NCT05213234
CP101 for the Treatment of Ulcerative Colitis
Brigham and Women's Hospital
NCT05852574
Angiographic Delivery of AD-MSC for Ulcerative Colitis
Mayo Clinic
NCT04312113
Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
Alimentiv
NCT03765450
Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)
Palatin Technologies
NCT05466890
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
University Hospitals Cleveland Medical Center
NCT00622557
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
Eli Lilly and Company
NCT03524092
A Comparison of Once a Day Dose Compared to 2 Doses/Day
Warner Chilcott
NCT00505778
Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease
Icahn School of Medicine at Mount Sinai
NCT02054533
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
Pfizer
NCT01458951
Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)
Bausch Health Americas
NCT01532648
Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)
University of North Carolina, Chapel Hill
NCT04852666
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
Bausch Health Americas
NCT00486031
Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission
Bausch Health Americas
NCT00326209
A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis
Shire
NCT01620255
Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
University of Maryland, Baltimore
NCT01692743
Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life
Icahn School of Medicine at Mount Sinai
NCT02322307
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
Pfizer
NCT02958865
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)
Ferring Pharmaceuticals
NCT02522780
Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis
Incara Pharmaceuticals
NCT00033943
Efficacy and Safety Study of Ozanimod in Ulcerative Colitis
Celgene
NCT01647516
Improving Medication Adherence in Pediatric Inflammatory Bowel Disease
Children's Hospital Medical Center, Cincinnati
NCT01536509
(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
Bausch Health Americas
NCT00801723
Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
NCT01349504
A Trial of Rosiglitazone for Ulcerative Colitis
James Lewis
NCT00065065
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis
AbbVie
NCT02065557
Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC)
Johns Hopkins University
NCT03669822
Fecal Biomarker Study for Patients With Ulcerative Colitis
Warner Chilcott
NCT00780507
Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease
Cedars-Sinai Medical Center
NCT00829595
An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy
Corewell Health West
NCT00467922
Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis
Novartis Pharmaceuticals
NCT00572585
A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
Lexicon Pharmaceuticals
NCT01456052
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 32 |
| Phase 3 | 28 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Ulcerative Colitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ulcerative Colitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ulcerative Colitis page
123 registered trials, 45 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 45 Ulcerative Colitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Ulcerative Colitis trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ulcerative Colitis condition card totals 123 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.